Modig Berndt sold $71K of PHVS
Modig Berndt (Chief Executive Officer) sold 2,291 shares of Pharvaris N.V. (PHVS) at an average of $31.07 ($31.05–$31.46) across 2 trades on 2026-06-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the CEO’s open-market sale of 2,291 shares on 2026-06-15 at ~$31.07 average, under a pre-arranged 10b5-1 plan.
Market read
This is a routine insider-sale filing; it may marginally affect sentiment but is unlikely to drive a sustained repricing without additional fundamental catalysts.
What to watch
The article doesn’t state whether there were concurrent buys, option exercises, or other insider activity; traders should check subsequent Form 4s for pattern changes.
Background
The article is an SEC Form 4 insider transaction disclosure for Pharvaris N.V. (PHVS).
Ticker impact
CEO Modig Berndt sold 2,291 PHVS shares in an open-market transaction on 2026-06-15 under a 10b5-1 plan, totaling $71,173.
Low near-term impact; any reaction likely fades unless follow-on selling accelerates or is paired with other negative news.
The filing is a Form 4 insider sale with stated 10b5-1 pre-arranged plan and modest dollar value versus typical market moves, implying informational content is limited.
Market effects
No sector-level read-through; this is company-specific insider transaction disclosure.
Minimal—no cross-market catalyst described.
Minimal—no international deal/regulatory/clinical catalyst mentioned.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still reflect management’s view of near-term risk or liquidity needs; monitor for clustering of sales.
Key entities
- issuerPharvaris N.V.
Subject of the Form 4 insider sale disclosure.
- insiderModig Berndt
CEO and director who sold PHVS shares under a 10b5-1 plan.
